This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D80.0 | Synonyms: Primary antibody deficiency (PAD), congenital agammaglobulinemia
The history of primary agammaglobulinemia begins with the pioneering report by Ogden C. Bruton in 1952, who found that the immunoglobulin fraction was absent on serum electrophoresis in an 8-year-old boy suffering from recurrent pneumonia and bacterial infections, and brought about clinical improvement by administering gamma globulin. This report, as the first clinical case demonstrating the importance of humoral immunity, made an important contribution to the history of immunology.
The classification system for primary immunodeficiency diseases developed from the 1960s to the 1980s. The World Health Organization (WHO) began systematically classifying primary immunodeficiency diseases in the 1970s, and since then the International Union of Immunological Societies (IUIS) has regularly updated the classification.
With identification of the BTK gene in 1993 and the subsequent sequential discovery of various causative genes such as IGHM, IGLL1, BLNK, CD79A, and CD79B, the molecular basis of primary agammaglobulinemia was established. This confirmed that primary agammaglobulinemia is not a single disease but a heterogeneous group of genetic disorders with a common phenotype.
In Korea, a diagnostic system for primary agammaglobulinemia was established along with the development of pediatric immunology in the 1980s–1990s. With the launch of the Korean primary immunodeficiency patient registry project, understanding of the patient population and treatment support gradually became more systematic.
Primary agammaglobulinemia refers to a condition in which immunoglobulins are not produced, or are produced in extremely small amounts, because of a genetic defect, without secondary causes (malignancy, drugs, protein loss, etc.). The modifier 'primary' distinguishes it in this respect from secondary agammaglobulinemia.
The common etiology of primary agammaglobulinemia is a block in B-cell development in the bone marrow. Various genetic abnormalities, such as BTK gene variants (XLA) and IGHM, IGLL1, CD79A, CD79B, and BLNK variants, block development from pro-B cells to mature B cells, causing the common agammaglobulinemia phenotype.
In some patients, no pathogenic variant is found in the currently known causative genes. This may be due to undiscovered causative genes, deep intronic variants, epigenetic dysregulation, etc., and research is ongoing.
The inheritance patterns of primary agammaglobulinemia include X-linked recessive (XLA, BTK variants), autosomal recessive (IGHM, IGLL1, CD79A/B, BLNK variants, etc.), and, rarely, autosomal dominant forms. The most common cause of primary agammaglobulinemia is XLA (about 85% of male patients), and the rest are due to various autosomal gene variants.
40–50% of all agammaglobulinemia patients are sporadic cases due to de novo variants without a family history. This is an important consideration in calculating recurrence risk during genetic counseling.
Accurate identification of the causative gene in primary agammaglobulinemia is essential for genetic counseling, prenatal diagnosis, and establishing a treatment strategy. Distinguishing XLA from autosomal recessive variants directly affects family planning.
The overall incidence of primary agammaglobulinemia is estimated at about 1 in 100,000–200,000 male newborns. It belongs to the most severe forms of primary antibody deficiency and is rarer than common variable immunodeficiency (CVID).
Because XLA accounts for most primary agammaglobulinemia, there is traditionally a male predominance (about 4:1), but as diagnoses of autosomal recessive forms increase, the proportion of female patients is also increasing.
In most cases symptoms first appear at 6–18 months of age, but mild cases are sometimes diagnosed after school age. The average time to diagnosis is 1–5 years, so education and increased awareness among health professionals are needed for early diagnosis.
Patients with primary agammaglobulinemia in Korea are registered in the integrated rare disease system, but accurate prevalence statistics are limited. Analysis of Health Insurance Review & Assessment Service (HIRA) data estimates the number of patients with D80 codes at tens to hundreds per year. The number of diagnoses is gradually increasing along with improvements in diagnostic technology.
The core pathophysiology of primary agammaglobulinemia is a block of B-cell development at a specific stage in the bone marrow. Normal B-cell development proceeds from hematopoietic stem cell→common lymphoid progenitor→pro-B cell→pre-B cell→immature B cell→mature B cell. Variants in genes such as BTK, IGHM, BLNK, and CD79A/B block the transition from pro-B to pre-B cells.
Because mature B cells and plasma cells are nearly or completely absent, virtually no immunoglobulin of any class (IgG, IgA, IgM, IgE, IgD) is produced. Antibody-mediated immunity is completely lost, so defense against encapsulated bacteria and viruses (especially enteroviruses) is severely impaired.
Primary agammaglobulinemia is a pure B-cell developmental defect, and T-cell function is preserved as normal. In this respect it differs from severe combined immunodeficiency (SCID), which has defects in both T and B cells. Because T-cell-dependent immunity (cellular immunity) is preserved, defense against some viral and fungal infections is maintained.
Repeated and recurrent bacterial infections after 6–18 months of age are characteristic. Pneumonia, sinusitis, otitis media, bacteremia, meningitis, and arthritis are the main infection patterns. Compared with ordinary children, the infections are more severe and more frequent; they respond to antibiotic treatment but recur.
Before immunoglobulin replacement therapy is started, or when treatment is insufficient, chronic meningoencephalitis caused by enteroviruses (echovirus, coxsackievirus) can occur. Delayed diagnosis leads to permanent neurological damage. Enterovirus-induced dermatomyositis-like syndrome is also a characteristic complication.
Chronic diarrhea due to Giardia lamblia, septic arthritis due to Campylobacter, and arthritis due to Mycoplasma may occur. Susceptibility to common opportunistic infections (Pneumocystis jirovecii, Candida, etc.) is relatively low.
Atrophic or absent tonsils and nonpalpable peripheral lymph nodes are characteristic. Abnormal chest auscultation due to recurrent pneumonia, bronchiectasis, and findings of chronic rhinorrhea and sinusitis. Growth retardation is often absent after long-term treatment, but growth impairment may occur in patients who had a long period of recurrent infections before treatment.
Serum IgG < 2 g/L (or below 2 SD of the lower limit of normal for age), IgA and IgM extremely low or undetectable. Peripheral blood CD19+ B cells < 2% or absolute count < 0.1 × 10⁹/L. T-cell (CD3+, CD4+, CD8+) counts and function normal. Absent specific antibody response after vaccination.
Chest CT: bronchiectasis and bronchiolectasis due to recurrent pneumonia. Head and neck CT: chronic sinusitis, mastoiditis. Joint X-ray: findings of bacterial or Mycoplasma arthritis.
Among the warning signs of primary immunodeficiency presented by the Jeffrey Modell Foundation and IUIS, the following are particularly relevant: two or more pneumonias in one year, four or more episodes of otitis media, recurrent deep skin/organ infections, two or more episodes of sepsis, infections not responding to antibiotic treatment, and a family member with primary immunodeficiency.
Quantification of serum IgG, IgA, and IgM and lymphocyte subset testing by flow cytometry (CD19+ B-cell percentage/absolute count, CD3+ T-cell analysis) are the basic screening tests. Results must be interpreted against age-specific normal values.
BTK protein expression is measured in monocytes (CD14+) by flow cytometry to rapidly determine whether XLA is present.
Diagnosis of primary agammaglobulinemia is made by integrating criteria such as ① marked reduction of serum IgG, IgA, and IgM, ② marked reduction or absence of peripheral blood B cells, ③ exclusion of secondary causes, and ④ confirmation of a causative gene variant.
BTK gene analysis (Sanger or NGS), a primary immunodeficiency gene panel (including IGHM, IGLL1, CD79A, CD79B, BLNK, PIK3R1, etc.), and whole exome/genome analysis are performed in a stepwise manner.
Secondary hypogammaglobulinemia due to malignant lymphoma, chronic lymphocytic leukemia, protein-losing enteropathy, nephrotic syndrome, or use of immunosuppressants must be excluded.
Intravenous immunoglobulin (IVIG, 400–600 mg/kg/3–4 weeks) or subcutaneous immunoglobulin (SCIG) is the standard treatment. The goal is maintaining an IgG trough level of 8 g/L or higher, with a target of 10 g/L or higher when there are pulmonary complications such as bronchiectasis. IgRT should be started immediately upon diagnosis and continued for life.
Early antibiotic treatment is essential for acute infections. Chest physiotherapy and airway clearance techniques for bronchiectasis are also used concurrently.
Live vaccines such as oral polio vaccine (OPV), varicella vaccine, and BCG are absolutely contraindicated in primary agammaglobulinemia. Caution is also needed regarding the use of live vaccines by family members.
Before the introduction of IgRT, most patients died in childhood from severe infectious complications. Patients now receiving regular IgRT survive into adulthood and can maintain a relatively normal quality of life.
When diagnosis is delayed, bronchiectasis, reduced lung function, and sequelae of central nervous system enterovirus infection may already have developed, in which case the long-term prognosis is poor. Chronic lung disease is the main cause of morbidity and mortality. With appropriate IgRT and infection management, life expectancy and quality of life can be kept close to normal.
Genetic counseling and carrier testing are important in the families of diagnosed patients. When XLA is diagnosed, the mother's carrier status is checked and male siblings are screened. For autosomal recessive forms, siblings and parents are tested and a prenatal diagnosis plan is established.
The key to prevention in primary agammaglobulinemia is starting IgRT immediately after early diagnosis. The longer the diagnostic delay, the more pulmonary complications and central nervous system damage accumulate, so increased awareness among health professionals is important.
Patients and caregivers must be educated about the absolute contraindication of live vaccines. Particular caution is needed regarding oral polio vaccine.